We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

64 hedge funds and large institutions have $201M invested in Ocular Therapeutix in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more call options, than puts

Call options by funds: $788K | Put options by funds: $162K

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

2% more capital invested

Capital invested by funds: $197M → $201M (+$3.54M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

10% less funds holding

Funds holding: 71 → 64 (-7)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Holders
64
Holders Change
-7
Holders Change %
-9.86%
% of All Funds
1.7%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
9
Increased
21
Reduced
12
Closed
16
Calls
$788K
Puts
$162K
Net Calls
+$626K
Net Calls Change
+$401K

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$4.91M
2
B
Bailard
California
+$1.66M
3
CI
Cowen Inc
New York
+$990K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$680K
5
CCI
Columbus Circle Investors
+$649K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.02M
2
Millennium Management
Millennium Management
New York
-$2.6M
3
O
OrbiMed
New York
-$1.45M
4
PCM
Portolan Capital Management
Massachusetts
-$1.42M
5
ARTA
A.R.T. Advisors
New York
-$898K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
51
Panagora Asset Management
Massachusetts
$30K +$23.5K +3,100 New
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$29K +$1.84K +243 +9%
Barclays
53
Barclays
United Kingdom
$18K -$24.3K -3,209 -61%
Teacher Retirement System of Texas
54
Teacher Retirement System of Texas
Texas
$15K +$2.51K +331 +28%
UBS Group
55
UBS Group
Switzerland
$14K -$34.8K -4,588 -75%
Bank of America
56
Bank of America
North Carolina
$12K -$23.7K -3,133 -72%
BlackRock
57
BlackRock
New York
$9K +$5.06K +668 +207%
CLOS
58
Compagnie Lombard Odier SCmA
Switzerland
$7K – – –
US Bancorp
59
US Bancorp
Minnesota
$7K – – –
CG
60
Cutler Group
California
$7K +$6.06K +800 New
ASN
61
Advisory Services Network
Georgia
$5K – – –
TDC
62
Thompson Davis & Co
Virginia
$1K – – –
VIA
63
Vantage Investment Advisors
Pennsylvania
$1K – – –
Geode Capital Management
64
Geode Capital Management
Massachusetts
$680 +$7.89K +1,042 +2%
Millennium Management
65
Millennium Management
New York
– -$2.6M -276,978 Closed
O
66
OrbiMed
New York
– -$1.45M -155,000 Closed
PCM
67
Portolan Capital Management
Massachusetts
– -$1.42M -151,292 Closed
ARTA
68
A.R.T. Advisors
New York
– -$898K -95,877 Closed
SM
69
Sabby Management
Florida
– -$843K -90,000 Closed
DCM
70
Driehaus Capital Management
Illinois
– -$387K -41,345 Closed
LCM
71
Landscape Capital Management
New Jersey
– -$334K -35,665 Closed
USAA
72
United Services Automobile Association
Texas
– -$324K -34,630 Closed
NI
73
Numeric Investors
Massachusetts
– -$135K -14,400 Closed
TI
74
Trexquant Investment
Connecticut
– -$129K -13,731 Closed
Tudor Investment Corp
75
Tudor Investment Corp
Connecticut
– -$119K -12,700 Closed
1 2
3
4

OCUL Hedge Fund Activity: Q1 2016 in Review

64 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2016, worth a combined $201M — up 1.8% from $197M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of OCUL and 9 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 21 added.

The largest buyer was Jennison Associates, adding an estimated $4.91M. The largest seller was Fidelity Investments, cutting an estimated $4.02M.

  • 64 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2016, down from 71 in Q4 2015.
  • Funds reported $201M of Ocular Therapeutix stock for Q1 2016, up 1.8% quarter-over-quarter.
  • 9 funds opened new Ocular Therapeutix positions in Q1 2016 and 16 closed out, a net change of -7 holders.
  • The largest Ocular Therapeutix buyer in Q1 2016 was Jennison Associates, an estimated $4.91M added.
  • The largest Ocular Therapeutix seller in Q1 2016 was Fidelity Investments, an estimated $4.02M sold.

Based on aggregated 13F filings for Q1 2016.